Literature DB >> 28652241

Prophylactic Treatment with VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection.

Teclegiorgis Gebremariam1, Sondus Alkhazraji1, Lin Lin1,2, Nathan P Wiederhold3, Edward P Garvey4, William J Hoekstra4, Robert J Schotzinger4, Thomas F Patterson3,5, Scott G Filler1,2, Ashraf S Ibrahim6,2.   

Abstract

We compared prophylactic or continuous therapy with the investigational drug VT-1161 to that with posaconazole in treating murine mucormycosis due to Rhizopus arrhizus var. arrhizus In the prophylaxis studies, only VT-1161 resulted in improved survival and lowered tissue fungal burden of immunosuppressed infected mice. In the continuous therapy, VT-1161 outperformed posaconazole in prolonging mouse survival time despite its comparable effect in lowering tissue fungal burden. These results support the further development of VT-1161 against mucormycosis.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Rhizopus arrhizus; VT-1161; mucormycosis; murine; prophylaxis

Mesh：

Substances：

Year:  2017        PMID： 28652241      PMCID： PMC5571349          DOI： 10.1128/AAC.00390-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.

Authors:  Kieren A Marr; Rachel A Carter; Fulvio Crippa; Anna Wald; Lawrence Corey
Journal:  Clin Infect Dis       Date:  2002-02-26       Impact factor: 9.079

2.  Zygomycosis: reemergence of an old pathogen.

Authors:  Carol A Kauffman
Journal:  Clin Infect Dis       Date:  2004-07-30       Impact factor: 9.079

3.  Design and optimization of highly-selective fungal CYP51 inhibitors.

Authors:  William J Hoekstra; Edward P Garvey; William R Moore; Stephen W Rafferty; Christopher M Yates; Robert J Schotzinger
Journal:  Bioorg Med Chem Lett       Date:  2014-06-09       Impact factor: 2.823

4.  Zygomycosis in the 1990s in a tertiary-care cancer center.

Authors:  D P Kontoyiannis; V C Wessel; G P Bodey; K V Rolston
Journal:  Clin Infect Dis       Date:  2000-06-13       Impact factor: 9.079

5.  A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007).

Authors:  F Lanternier; E Dannaoui; G Morizot; C Elie; D Garcia-Hermoso; M Huerre; D Bitar; F Dromer; O Lortholary
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

6.  Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis.

Authors:  Ashraf S Ibrahim; Joel C Bowman; Valentina Avanessian; Keturah Brown; Brad Spellberg; John E Edwards; Cameron M Douglas
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

7.  Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis.

Authors:  Greg T Siwek; Kirsty J Dodgson; Margarida de Magalhaes-Silverman; Luther A Bartelt; Sara B Kilborn; Peter L Hoth; Daniel J Diekema; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2004-07-30       Impact factor: 9.079

8.  VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection.

Authors:  Teclegiorgis Gebremariam; Nathan P Wiederhold; Annette W Fothergill; Edward P Garvey; William J Hoekstra; Robert J Schotzinger; Thomas F Patterson; Scott G Filler; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2015-09-14       Impact factor: 5.191

9.  Invasive zygomycosis in India: experience in a tertiary care hospital.

Authors:  A Chakrabarti; S S Chatterjee; A Das; N Panda; M R Shivaprakash; A Kaur; S C Varma; S Singhi; A Bhansali; V Sakhuja
Journal:  Postgrad Med J       Date:  2009-11       Impact factor: 2.401

10.  Evaluation of VT-1161 for Treatment of Coccidioidomycosis in Murine Infection Models.

Authors:  Lisa F Shubitz; Hien T Trinh; John N Galgiani; Maria L Lewis; Annette W Fothergill; Nathan P Wiederhold; Bridget M Barker; Eric R G Lewis; Adina L Doyle; William J Hoekstra; Robert J Schotzinger; Edward P Garvey
Journal:  Antimicrob Agents Chemother       Date:  2015-09-14       Impact factor: 5.191
View more
  10 in total

1.  Azole Resistance Reduces Susceptibility to the Tetrazole Antifungal VT-1161.

Authors:  Brian C Monk; Mikhail V Keniya; Manya Sabherwal; Rajni K Wilson; Danyon O Graham; Harith F Hassan; Danni Chen; Joel D A Tyndall
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

Review 2.  Challenges in the diagnosis and treatment of mucormycosis.

Authors:  A Skiada; C Lass-Floerl; N Klimko; A Ibrahim; E Roilides; G Petrikkos
Journal:  Med Mycol       Date:  2018-04-01       Impact factor: 4.076

Review 3.  Current Treatment Options for COVID-19 Associated Mucormycosis: Present Status and Future Perspectives.

Authors:  Yasasve Madhavan; Kadambari Vijay Sai; Dilip Kumar Shanmugam; Aashabharathi Manimaran; Karthigadevi Guruviah; Yugal Kishore Mohanta; Divyambika Catakapatri Venugopal; Tapan Kumar Mohanta; Nanaocha Sharma; Saravanan Muthupandian
Journal:  J Clin Med       Date:  2022-06-23       Impact factor: 4.964

Review 4.  Therapy of Mucormycosis.

Authors:  Nikolaos V Sipsas; Maria N Gamaletsou; Amalia Anastasopoulou; Dimitrios P Kontoyiannis
Journal:  J Fungi (Basel)       Date:  2018-07-31

Review 5.  The Fungal CYP51s: Their Functions, Structures, Related Drug Resistance, and Inhibitors.

Authors:  Jingxiang Zhang; Liping Li; Quanzhen Lv; Lan Yan; Yan Wang; Yuanying Jiang
Journal:  Front Microbiol       Date:  2019-04-24       Impact factor: 5.640

Review 6.  Mucormycosis of the Central Nervous System.

Authors:  Amanda Chikley; Ronen Ben-Ami; Dimitrios P Kontoyiannis
Journal:  J Fungi (Basel)       Date:  2019-07-08

Review 7.  Roles for Structural Biology in the Discovery of Drugs and Agrochemicals Targeting Sterol 14α-Demethylases.

Authors:  Brian C Monk; Mikhail V Keniya
Journal:  J Fungi (Basel)       Date:  2021-01-20

Review 8.  Novel antifungal agents in clinical trials.

Authors:  Samantha E Jacobs; Panagiotis Zagaliotis; Thomas J Walsh
Journal:  F1000Res       Date:  2021-06-28

Review 9.  Current treatments against mucormycosis and future directions.

Authors:  Courtney Smith; Soo Chan Lee
Journal:  PLoS Pathog       Date:  2022-10-13       Impact factor: 7.464

Review 10.  Advances in anti-fungal therapies.

Authors:  Grant Waterer
Journal:  Mycopathologia       Date:  2021-07-15       Impact factor: 2.574
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.